Long-Term Safety of Pirtobrutinib in Participants From Study LOXO-BTK-20020 With BTKi Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Long-Term Safety of Pirtobrutinib in Participants From Study LOXO-BTK-20020 With BTKi Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
This study will evaluate the long-term safety of pirtobrutinib in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study is open to those who completed J2N-MC-JZNN/LOXO-BTK-20020 (NCT 04666038) for continued access to the study intervention or continued follow-up visits. Treatment will be given every 4 weeks and this study is expected to last about 5 years.
Inclusion Criteria:
Exclusion Criteria:
LillyTrials@Lilly.com1-317-615-4559
clinical_inquiry_hub@lilly.com
Mobile, Alabama 36693, United States
334-660-5108
New York, New York 10065-6007, United States
Toronto, M5G 2M9, Canada
Budapest, 1097, Hungary
Alessandria, 15121, Italy
Perugia, 06129, Italy
Brzozów, 36-200, Poland
Bydgoszcz, 85-168, Poland
520-886-0206
904-538-4488
612-884-6300
646-608-4273
513-751-2273
214-370-1000
210-595-5300
61396561111
+435725525822
+3251237322
4169462827
+8613691066953
+8613798032244
+8613725119762
+8613519607327
+86079188693682
+862164175590
+8613515861286
+8622023909015
+8618622221227
+869917968088
+86516085802297
+864000371818
+38512388675
+420495834851
+33232082223
+3614558217
+3652255196
+353868703651
+35318092010
97236973576
+390131207825
+39557947958
+39903992246
+390392331
+39755783990
+390630156016
+39744205971
81120023812
+48134309728
+48795149026
+48600388282
+34942202520
+34955013277
+441482461296
+441132433144
+44 1223 816789